FRANKFURT (Reuters) - German private equity firm Aurelius said on Monday it is buying Reckitt Benckiser's (L:RB) Scholl shoe business in its efforts to expand internationally, betting on the brand's growth potential.
Under the agreement, Aurelius would acquire the international rights for the Scholl footwear business, excluding North and South America.
The rights to that business in the Americas will go to German drugmaker Bayer (DE:BAYGn) as part of its $14 billion (8.19 billion pounds) purchase of Merck & Co's (N:MRK) consumer health business.
Aside from the Scholl shoe business, which is known for its focus on comfort, Reckitt Benckiser has a Scholl-branded footcare business that includes insoles and blister bandages.
Aurelius, which did not disclose financial details of the deal, said it plans to develop the brand by introducing new products and expanding in new markets.
While Scholl footwear is mostly known in western and southern European countries such as France and Italy, it is not on sale in Aurelius's home market, Germany.
Last year the business achieved sales of about 90 million euros (71 million pounds), the statement said.
The transaction is expected to close in the third quarter of 2014 and is subject to regulatory approvals, Aurelius said.
(Reporting by Kirsti Knolle and Martinne Geller; Editing by David Goodman)
Should you invest $2,000 in MRK right now?
With MRK making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed MRK alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including MRK, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is MRK poised for similar growth? Don't miss the opportunity to find out.
Reveal Undervalued Stocks Now